197 related articles for article (PubMed ID: 19430406)
1. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma.
Leiter U; Marghoob AA; Lasithiotakis K; Eigentler TK; Meier F; Meisner C; Garbe C
Melanoma Res; 2009 Feb; 19(1):50-7. PubMed ID: 19430406
[TBL] [Abstract][Full Text] [Related]
2. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging.
Meyers MO; Yeh JJ; Frank J; Long P; Deal AM; Amos KD; Ollila DW
Ann Surg Oncol; 2009 Apr; 16(4):941-7. PubMed ID: 19101766
[TBL] [Abstract][Full Text] [Related]
3. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
[TBL] [Abstract][Full Text] [Related]
4. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy.
Moore Dalal K; Zhou Q; Panageas KS; Brady MS; Jaques DP; Coit DG
Ann Surg Oncol; 2008 Aug; 15(8):2206-14. PubMed ID: 18512102
[TBL] [Abstract][Full Text] [Related]
5. Melanoma staging: facts and controversies.
Forschner A; Eigentler TK; Pflugfelder A; Leiter U; Weide B; Held L; Meier F; Garbe C
Clin Dermatol; 2010; 28(3):275-80. PubMed ID: 20541679
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of reduced follow-up in malignant melanoma.
Hengge UR; Wallerand A; Stutzki A; Kockel N
J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
[TBL] [Abstract][Full Text] [Related]
7. A rational approach to the follow-up of melanoma patients.
Garbe C
Recent Results Cancer Res; 2002; 160():205-15. PubMed ID: 12079215
[TBL] [Abstract][Full Text] [Related]
8. Follow-up in patients with localised primary cutaneous melanoma.
Francken AB; Bastiaannet E; Hoekstra HJ
Lancet Oncol; 2005 Aug; 6(8):608-21. PubMed ID: 16054572
[TBL] [Abstract][Full Text] [Related]
9. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
11. Changing trends in melanoma treatment and the expanding role of the dermatologist.
Brown MD; Johnson TM; Swanson NA
Dermatol Clin; 1991 Oct; 9(4):657-67. PubMed ID: 1934641
[TBL] [Abstract][Full Text] [Related]
12. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines.
Francken AB; Shaw HM; Accortt NA; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2007 Jun; 14(6):1924-33. PubMed ID: 17357855
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy.
Garbe C; Paul A; Kohler-Späth H; Ellwanger U; Stroebel W; Schwarz M; Schlagenhauff B; Meier F; Schittek B; Blaheta HJ; Blum A; Rassner G
J Clin Oncol; 2003 Feb; 21(3):520-9. PubMed ID: 12560444
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous melanoma: baseline and ongoing laboratory evaluation.
Garbe C
Dermatol Ther; 2005; 18(6):413-21. PubMed ID: 16297017
[TBL] [Abstract][Full Text] [Related]
15. [Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up].
Francken AB; Thompson JF; Bastiaannet E; Hoekstra HJ
Ned Tijdschr Geneeskd; 2008 Mar; 152(10):557-62. PubMed ID: 18402322
[TBL] [Abstract][Full Text] [Related]
16. Staging work-up and post-treatment surveillance of patients with melanoma.
Olson JA; Jaques DP; Coit DG; Hwu WJ
Clin Plast Surg; 2000 Jul; 27(3):377-90, viii. PubMed ID: 10941559
[TBL] [Abstract][Full Text] [Related]
17. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry.
Leiter U; Buettner PG; Eigentler TK; Bröcker EB; Voit C; Gollnick H; Marsch W; Wollina U; Meier F; Garbe C
J Am Acad Dermatol; 2012 Jan; 66(1):37-45. PubMed ID: 21700361
[TBL] [Abstract][Full Text] [Related]
18. Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival.
Hofmann U; Szedlak M; Rittgen W; Jung EG; Schadendorf D
Br J Cancer; 2002 Jul; 87(2):151-7. PubMed ID: 12107834
[TBL] [Abstract][Full Text] [Related]
19. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.
Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A
Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589
[TBL] [Abstract][Full Text] [Related]
20. [Malignant melanoma: which examinations are useful in staging and follow-up?].
Goerz G; Schulte-Beerbühl R; Roder K; Schoppe WD; Münchhoff C; Jungblut RM
Dtsch Med Wochenschr; 1986 Aug; 111(33):1230-3. PubMed ID: 3527640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
